India is expected to roll out a new drug policy and devise rules for clinical trials that may bring new projects to the country, a top Indian official has said. A team of Indian officials led by Dr. G N Singh, Drug Controller General of India, informed that a set of new procedures to facilitate clinical trials are expected to be unveiled shortly.
The Indian government is working with stakeholders to devise new rules for clinical trials that are expected to bring new projects to India.
Over the last few years, clinical trials in India slowed down amid tedious court litigation and rising protests from health activists on issues related to informed consent and compensation norms, an official statement said.
The government, in consultation with stakeholders, has devised new rules that will require more information of the patients enrolling themselves for clinical trials. The officials will make efforts to integrate scattered laboratories that can help avoid duplication of research and accelerate the process of drug development. The government will intend to work on three broad categories: harmonise standards, convergence of regulatory practices and avoid duplication.